Lantus

Insulin glargine

Adult, adolescent & childn ≥2 yr w/ DM where treatment w/ insulin is required.

SC Administer once daily at any time but at the same time every day. Dose & timing of dose should be individually adjusted. Can be given w/ orally active antidiabetics in patients w/ type II DM.

Hypersensitivity.

Not to be administered IV. Do not mix w/ other insulin or be diluted. Not for the treatment of diabetic ketoacidosis. Transferring a patient to another type or brand of insulin. Hypoglycemia. Patients at risk are in whom glycaemic control is markedly improved, hypoglycaemia develops gradually, elderly, after transfer from animal insulin to human insulin, in whom an autonomic neuropathy is present, w/ long history of diabetes, psychiatric illness. Increased susceptibility to hypoglycaemia in patients who change in the inj area, increase of insulin sensitivity (eg, by removal of stress factors); unaccustomed, increased or prolonged physical exercise, intercurrent illness (eg, vomiting, diarrhoea), inadequate food intake, missed meals, alcohol consumption, certain uncompensated endocrine disorders, (eg, hypothyroidism & anterior pituitary or adrenocortical insufficiency). Intensified metabolic monitoring in patients w/ intercurrent illness. May cause insulin antibody formation. Always check insulin label before each inj to avoid medication errors between insulin glargine & other insulins. Cases of cardiac failure in combination w/ pioglitazones. Discontinue if any deterioration in cardiac symptoms occurs. in Hepatic & renal impairment. May impair ability to drive or operate machinery. Lactation. Childn <2 yr.

Hypoglycemia. Lipodystrophy, inj site reactions including redness, pain, itching, hives, swelling or inflammation. Temporary visual impairment, Na retention, edema, retinopathy.

May enhance blood-glucose-lowering effect & increase susceptibility to hypoglycaemia w/ oral anti-diabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamides. May reduce the blood-glucose-lowering effect w/ corticosteroids; danazol, diazoxide, diuretics, glucagon, INH, estrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. May potentiate or weaken the blood glucose lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Hypoglycemia followed by hyperglycemia w/ pentamidine. Reduced or absent adrenergic counter regulation w/ sympatholytics eg, β-blockers, clonidine, guanethidine & reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

Rx